DESCRIPTION	TOTAL SAMPLE POPULATION	ESTIMATED RESPONSE RATE	ESTIMATED NUMBER OF RESPONDENTS	NUMBER OF RESPONSES PER RESPONDENT	TOTAL ANNUAL RESPONSES	TOTAL ANNUAL NON-RESPONSES	HOURS PER RESPONSE	TOTAL HOURS FOR RESPONDENTS	TOTAL HOURS NON RESPONSE
VS Form 21-200 2020 NAHMS Swine Large Enterprise Survey - Site Selection Form ¹	2,700	54.0%	1,458	1	1,458	1,242	1.00	1,458	99
VS Form 21-201 2020 NAHMS Swine Large Enterprise Survey $^{\!2}$	4,085	54.0%	2,206	1	2,206	1,879	1.51	3,331	319
VS Form 21-202 2020 NAHMS Swine Large Enterprise Consent form	2,206	53.6%	1,182	1	1,182	1,024	0.17	201	82
VS Form 21-203 2020 NAHMS Swine Large Enterprise - VS Visit ³	1,182	51.0%	603	1	603	579	1.27	766	7
VS Form 21-204 2020 NAHMS Swine Large Enterprise - Informed Consent	1,182	51.0%	603	1	603	579	0.17	102	98
VS Form 21-205 2020 NAHMS Swine Large Enterprise - Fecal Collection Record	603	24.8%	150	1	150	453	2.75	411	6
VS Form 21-206 2020 NAHMS Swine Large Enterprise - Saliva Collection Form	603	83.0%	500	1	500	103	2.00	1,001	1
VS Form 21-207 2020 NAHMS Swine Small Enterprise Survey ⁴	5,880	41.2%	2,423	1	2,423	3,457	1.24	3,005	277
TOTAL	9,965		4,629		9,125	9,316		10,275	890

NOTE: Actual number of hours may vary due to rounding

NOTE: Non-responses are assumed to be 10 minutes for VS Form 21-201 and VS Form 21-204 and 5 minutes for each remaining component of the study except for VS Forms 21-205, and 21-206. The decision to complete these components will be made while the respondent is completing VS Form 21-204 (Informed Consent). Non-response for these exceptions forms is assumed to be 0.5 minutes.

1 For the Larger Producer study, a total sample size of 2700 operations in 13 states will be surveyed. VS Form 21-200 will be administered to gather information about the sites on which hogs owned by the operation are raised. VS Form 21-201 will be administered to respondents of VS Form 21-202 to the site level. Respondents to VS Form 21-201 will have the chance to consent (using VS Form 21-202) to have the chance to consent (using VS Form 21-202) to have the chance to consent (using VS Form 21-202) to having their contact information turned over to APHIS for potential participation in completing VS Form 21-203, VS Form 21-204, VS Form 21-205, and VS Form 21-206.

- 2 The burden estimate for this item includes the time to complete the questionnaire itself (1.1 hours) plust the time to review the presurvey letter, launch sheet, a letter from the industry, and biologics testing/timeline material (0.08, 0.17, 0.08, and 0.08 hours, respectively).
- 3 The burden estimate for this item includes the time to complete the questionnaire itself (1.1 hours) plust the time expected for the VS questionnaire phone script to take (0.17 hours).
- 4 For the CATI component of the study, 5880 operation in 38 states will be surveyed using VS Form 21-207. The completion rate for this item includes both the expected in-scope portion of the sample (0.412, which is a reflection of the combination of the percentage of operations selected from the frame that would be considered in-scope for this portion of the sudy, 0.574, and, given the operation is in scope, the proportion of the sample that is expected to complete the questionnaire, 0.723). The burden estimate for this item includes the time to complete the questionnaire itself (1 hour) plus the time to review the presurvey letter, launch shee, and African Swine Fever (ASF) fact sheet that will be sent with the questionnaire (0.08 hours each).

A. Sampled subjects		9965.00				
B. Responses/Subject C/A=B		0.92				
C. Annual Responses	9125.46					
D. Total Burden	11165.26					
E. Estimate of Burden D/C=	1.22					
F. Estimate of responses per sampled subject	0.92					
G. Estimate of hours of response per sampled subject	1.03					
Response averages by participant type (in hours)						
	Response average					
Туре	-					
Large Enterprise component						
Nonrespondent	0.58					
Phase I respondent, Phase II nonrespondent	2.68					
Phase I respondent, Phase II nonrespondent, decline biologics	4.12					
Complete respondent (Phase I, Phase II, and biologics sampling)	10.38					
Small Enterprise component						
Nonrespondent	0.24					
Complete respondent	1.24					